Cullinan Therapeutics, Inc.
HealthcareNASDAQ:CGEM · NASDAQ Global Select
+$0.72 today
Vol 1.31M · Avg 0.93M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $75.1M |
| Short-term Investments | $276.8M |
| Other Current | $9.5M |
| Total Current Assets | $361.4M |
| PP&E (Net) | $2.8M |
| Long-term Investments | $38.5M |
| Other Non-current | $297.0K |
| Total Non-current Assets | $41.6M |
| Total Assets | $403.0M |
Analysis
Selected assets total $403.0M for Latest. The largest visible component is Short-term Investments at $276.8M, about 68.7% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $88.3M +6.4% | $83.0M -15.7% | $98.4M -37.0% | $156.2M +161.2% | $59.8M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $289.6M -8.4% | $316.0M -14.3% | $368.6M +18.5% | $311.1M +34.9% | $230.7M | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $0 -100.0% | $3.0M | $0 | $0 | $0 | $533.8M | $399.4M | -$1.7B |
| Inventory | $0 | $0 | $0 | $0 | $0 | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $8.9M -30.2% | $12.7M -3.3% | $13.1M +82.8% | $7.2M | $0 | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $386.8M -6.7% | $414.7M -13.6% | $480.2M +1.2% | $474.5M +60.0% | $296.6M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $3.1M +29.8% | $2.4M -33.5% | $3.5M -33.4% | $5.3M +6788.3% | $77.0K | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $58.3M -71.5% | $204.4M | $0 -100.0% | $80.9M -42.4% | $140.4M | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $297.0K -18.9% | $366.0K -20.3% | $459.0K +0.0% | $459.0K +212.2% | $147.0K | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $61.6M -70.3% | $207.2M +5090.6% | $4.0M -95.4% | $86.6M -38.4% | $140.6M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $448.4M -27.9% | $621.8M +28.4% | $484.2M -13.7% | $561.1M +28.3% | $437.2M | $13.3B | $11.9B | $10.6B |
| Account Payables | $841.0K -50.0% | $1.7M -32.5% | $2.5M -6.3% | $2.7M -16.1% | $3.2M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $780.0K | $0 | $0 -100.0% | $178.0K | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 -100.0% | $4.3M | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $36.1M +2413.6% | $1.4M -81.8% | $7.9M +304.1% | $2.0M -44.9% | $3.5M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $37.7M +23.1% | $30.6M +8.9% | $28.1M +25.1% | $22.5M +91.5% | $11.7M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $1.9M | $0 | $0 | $0 | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $0 | $0 | $0 | $0 -100.0% | $65.0K | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $1.9M +124.1% | $849.0K -60.5% | $2.1M -40.1% | $3.6M +5423.1% | $65.0K | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $39.6M +25.9% | $31.5M +4.0% | $30.3M +16.1% | $26.1M +120.9% | $11.8M | $14.7B | $3.7B | $9.6B |
| Common Stock | $6.0K +0.0% | $6.0K +50.0% | $4.0K -20.0% | $5.0K +25.0% | $4.0K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$588.1M -59.7% | -$368.2M -83.3% | -$200.9M -321.1% | -$47.7M +70.0% | -$158.9M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $1.0M +866.9% | -$133.0K -3.1% | -$129.0K +95.0% | -$2.6M -210.4% | -$838.0K | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 -100.0% | $192.0K | $0 -100.0% | $403.0K | $1.4B | $337.8M | $931.4M |
| Total Equity | $408.7M -30.8% | $590.3M +30.1% | $453.9M -15.2% | $535.0M +25.8% | $425.4M | $9.1B | $7.7B | $3.3B |
| Total Debt | $2.7M +24.7% | $2.2M -40.1% | $3.6M -30.8% | $5.2M | $0 | $724.2M | $410.6M | $399.4M |
| Net Debt | -$85.6M -5.9% | -$80.9M +14.8% | -$94.8M +37.2% | -$151.0M -152.6% | -$59.8M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
RAPT Therapeutics, Inc.
RAPT
$959.26M
Enhabit, Inc.
EHAB
$706.91M
CeriBell, Inc.
NASDAQ:CBLL
$700.80M
Omeros Corporation
NASDAQ:OMER
$632.20M
Varex Imaging Corporation
NASDAQ:VREX
$464.78M
Standard BioTools Inc.
NASDAQ:LAB
$346.53M
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
$329.81M
Bicycle Therapeutics plc
NASDAQ:BCYC
$281.05M
So-Young International Inc.
NASDAQ:SY
$244.05M
ADC Therapeutics S.A.
NYSE:ADCT
$133.55M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does CGEM have?
Cullinan Therapeutics, Inc. (CGEM) reported $88.33M in cash and equivalents in fiscal 2025.
How much debt does CGEM carry?
Cullinan Therapeutics, Inc. (CGEM) reported $2.68M of total debt, with net debt of -$85,649,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.